Nature Reviews Endocrinology

Article	Citations
COVID-19 and diabetes mellitus: from pathophysiology to clinical management	677
Exerkines in health, resilience and disease	395
Mitochondrial and metabolic dysfunction in ageing and age-related diseases	394
The burden and risks of emerging complications of diabetes mellitus	392
The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases	377
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19	346
Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)	335
Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics	293
Current understanding of the molecular and cellular pathology of diabetic retinopathy	275
Type 2 diabetes mellitus in older adults: clinical considerations and management	268
The health effects of vitamin D supplementation: evidence from human studies	267
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus	259
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease	235
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy	233
Autophagy in metabolic disease and ageing	213
Endocrine toxicities of immune checkpoint inhibitors	198
Metformin: update on mechanisms of action and repurposing potential	193
Current practice in patients with differentiated thyroid cancer	192
Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver	191
The role of insufficient sleep and circadian misalignment in obesity	178
Environmental factors in declining human fertility	173
Lipid droplet biogenesis and functions in health and disease	153
Clinical application of intermittent fasting for weight loss: progress and future directions	142
Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus	130
Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus	118

Metabolic pathways in obesity-related breast cancer	111
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement	109
Paracetamol use during pregnancy — a call for precautionary action	109
Macrophage functional diversity in NAFLD — more than inflammation	108
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations	105
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD	102
Epigenetic inheritance of polycystic ovary syndrome — challenges and opportunities for treatment	101
The evolving view of thermogenic adipocytes — ontogeny, niche and function	99
The gut microbiota in obesity and weight management: microbes as friends or foe?	95
Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions	92
The importance of the RET gene in thyroid cancer and therapeutic implications	91
International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers	91
Novel therapies with precision mechanisms for type 2 diabetes mellitus	89
Brain insulin signalling in metabolic homeostasis and disease	87
Aggressive pituitary tumours and pituitary carcinomas	80
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1	80
Assessment and treatment of thyroid disorders in pregnancy and the postpartum period	77
Clinical aspects of multiple endocrine neoplasia type 1	77
Functions of galanin, spexin and kisspeptin in metabolism, mood and behaviour	76
Metabolic implications of pancreatic fat accumulation	76
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis	76
Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus	75
The physiological role of β-cell heterogeneity in pancreatic islet function	75
A global view of hypertensive disorders and diabetes mellitus during pregnancy	74
International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia	69
One hundred years of insulin therapy	69
Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities	68
The multiple roles of life stress in metabolic disorders	67
Primary hypothyroidism and quality of life	66
Hormonal regulation of mammary gland development and lactation	66
Targeting lipid GPCRs to treat type 2 diabetes mellitus — progress and challenges	66
Cellular and molecular features of EDC exposure: consequences for the GnRH network	65
The role of iron in host–microbiota crosstalk and its effects on systemic glucose metabolism	63
The G protein-coupled oestrogen receptor GPER in health and disease: an update	61
Hormonal regulation of biomineralization	61
Hepatic sexual dimorphism — implications for non-alcoholic fatty liver disease	61
Uterine bleeding: how understanding endometrial physiology underpins menstrual health	61
Long-term and sequential treatment for osteoporosis	60
Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia	60
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases	59
Skeletal disorders associated with the growth hormone–insulin-like growth factor 1 axis	58
Management challenges and therapeutic advances in congenital adrenal hyperplasia	57
Treating menopause — MHT and beyond	55
Global accessibility of therapeutics for diabetes mellitus	55
The role of biomineralization in disorders of skeletal development and tooth formation	54
Multifaceted actions of melanin-concentrating hormone on mammalian energy homeostasis	54
Metabolic disorders, COVID-19 and vaccine-breakthrough infections	52
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits	50
Optoacoustic imaging in endocrinology and metabolism	50
Primary aldosteronism — a multidimensional syndrome	48

Epigenetics of type 2 diabetes mellitus and weight change — a tool for precision medicine?	47
Multikinase inhibitors in thyroid cancer: timing of targeted therapy	45
The role of regulated necrosis in endocrine diseases	42
Advances in differential diagnosis and management of growth hormone deficiency in children	42
Intermuscular adipose tissue in metabolic disease	40
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus	40
Modelling metabolic diseases and drug response using stem cells and organoids	40
Long COVID — metabolic risk factors and novel therapeutic management	37
Adrenal cortex renewal in health and disease	37
Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia	36
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice	35
Heterogeneity and endotypes in type 1 diabetes mellitus	35
Skeletal and extraskeletal disorders of biomineralization	34
The interplay between diabetes mellitus and menopause: clinical implications	34
Exercise in adults with type 1 diabetes mellitus	33
Consensus Statement on the definition and classification of metabolic hyperferritinaemia	31
Challenges in the care of transgender and gender-diverse youth: an endocrinologist’s view	31
How can social jetlag affect health?	30
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation	30
Insights into non-classic and emerging causes of hypopituitarism	30
The regulation of endocrine-disrupting chemicals to minimize their impact on health	30
Potential gut–brain mechanisms behind adverse mental health outcomes of bariatric surgery	30
Type 2 diabetes mellitus in sub-Saharan Africa: challenges and opportunities	30
X chromosome agents of sexual differentiation	29
Machine intelligence in non-invasive endocrine cancer diagnostics	29
The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects	28
SGLT2 inhibitors in people with and without T2DM	27
Strategies for modelling endometrial diseases	27
The role of ChREBP in carbohydrate sensing and NAFLD development	27
Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease	26
The importance of metabolic dysfunction in polycystic ovary syndrome	26
Is there a role for the adrenal glands in long COVID?	25
Metabolic determinants of tumour initiation	25
Sarcopenic obesity in older adults: a clinical overview	24
Immune dysfunction in developmental programming of type 2 diabetes mellitus	23
Lactate as a major myokine and exerkine	22
Why does the immune system destroy pancreatic β-cells but not α-cells in type 1 diabetes?	22
Towards a better understanding of diabetes mellitus using organoid models	22
Insulin detection in diabetes mellitus: challenges and new prospects	21
Exosomes as novel biomarkers in metabolic disease and obesity-related cancers	21
The evolving functions of the vasculature in regulating adipose tissue biology in health and obesity	20
COVID-19 alters thinking and management in metabolic diseases	20
Adipose tissue in communication: within and without	20
Fetoplacental oxygen homeostasis in pregnancies with maternal diabetes mellitus and obesity	19
Pituitary crosstalk with bone, adipose tissue and brain	19
Mammalian models of diabetes mellitus, with a focus on type 2 diabetes mellitus	19
Progress in islet transplantation is more important than ever	19
Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?	18
Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer	18
High resolution 3D structures of mineralized tissues in health and disease	18
A spectacular year for islet and stem cell transplantation	18
Metabolism and exercise: the skeletal muscle clock takes centre stage	18
An integrated model of obesity pathogenesis that revisits causal direction	17
Diagnostic and therapeutic advances in neuroendocrine tumours	17
Severe COVID-19 outcomes — the role of physical activity	17
Applying the WHO global targets for diabetes mellitus	16
Improving clinical outcomes through attention to sex and hormones in research	16
Obesity-induced and weight-loss-induced physiological factors affecting weight regain	16
Endosomal trafficking in metabolic homeostasis and diseases	16
Programming of metabolism by adipokines during development	15
Emerging mechanisms of obesity-associated immune dysfunction	15
Genomic alterations in thyroid cancer: biological and clinical insights	15
Targeting the central melanocortin system for the treatment of metabolic disorders	14
The emerging evidence for non-skeletal health benefits of vitamin D supplementation in adults	14
Current and future pharmacotherapies for obesity in children and adolescents	14
The genetics of autoimmune Addison disease: past, present and future	14
SARS-CoV-2 fires up inflammation in adipose tissue	13
An individualized approach to the management of Cushing disease	13
Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement	13
The manifold roles of protein S-nitrosylation in the life of insulin	13
Kid influencers — a new arena of social media food marketing	12
Obesity and the kidney: mechanistic links and therapeutic advances	12
Taking a closer look at metabolically healthy obesity	11
Adrenal cysts: an emerging condition	11
Weight stigma in healthcare settings is detrimental to health and must be eradicated	11
Is the association between diabetes mellitus and pulmonary fibrosis real?	11
Paracetamol use in pregnancy — caution over causal inference from available data	11
New anti-osteoporosis drug target identified	11
Clustering for a better prediction of type 2 diabetes mellitus	11
Drug resistance in pituitary tumours: from cell membrane to intracellular signalling	10

Could leptin substitution therapy potentially terminate entrapment in anorexia nervosa?	10
High-intensity exercise training — too much of a good thing?	10
Handle with care — interpretation, synthesis and dissemination of data on paracetamol in pregnancy	10